M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine.

@article{Witkin2014M1AM,
  title={M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine.},
  author={Jeffrey M. Witkin and Carl D. Overshiner and Xia Li and John Catlow and Graham N. Wishart and Douglas A Schober and Beverly A. Heinz and Alexander Nikolayev and Vladimir V Tolstikov and Wesley H. Anderson and Richard E. Higgs and M-S Kuo and Christian C. Felder},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2014},
  volume={351 2},
  pages={
          448-56
        }
}
Scopolamine produces rapid and significant symptom improvement in patients with depression, and most notably in patients who do not respond to current antidepressant treatments. Scopolamine is a nonselective muscarinic acetylcholine receptor antagonist, and it is not known which one or more of the five receptor subtypes in the muscarinic family are mediating these therapeutic effects. We used the mouse forced-swim test, an antidepressant detecting assay, in wild-type and transgenic mice in… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 59 REFERENCES

Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 1999
VIEW 4 EXCERPTS

New paradigms for treatment-resistant depression.

  • Annals of the New York Academy of Sciences
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Can a model with predictive validity for clinical efficacy in treatmentresistant depression be derived from the differential behavioral effects of drugs across mouse strains? (Abstract)

JM Witkin, K Rasmussen, +3 authors MP Kelly
  • Neuropsychopharmacology 36:S198–S323
  • 2011
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review

WC Drevets, CA Zarate, Jr., ML Furey
  • Biol Psychiatry
  • 2013
VIEW 2 EXCERPTS